Development of a Clinically Viable Heroin Vaccine

Overview

Journal J Am Chem Soc

Publisher American Chemical Society

Specialty Chemistry

Date 2017 Jun 3

PMID 28574716

Citations 47

Authors

Paul T Bremer

Joel E Schlosburg

Matthew L Banks

Floyd F Steele

Bin Zhou

Justin L Poklis

Kim D Janda

Affiliations

Soon will be listed here.

Abstract

Heroin is a highly abused opioid and incurs a significant detriment to society worldwide. In an effort to expand the limited pharmacotherapy options for opioid use disorders, a heroin conjugate vaccine was developed through comprehensive evaluation of hapten structure, carrier protein, adjuvant and dosing. Immunization of mice with an optimized heroin-tetanus toxoid (TT) conjugate formulated with adjuvants alum and CpG oligodeoxynucleotide (ODN) generated heroin "immunoantagonism", reducing heroin potency by >15-fold. Moreover, the vaccine effects proved to be durable, persisting for over eight months. The lead vaccine was effective in rhesus monkeys, generating significant and sustained antidrug IgG titers in each subject. Characterization of both mouse and monkey antiheroin antibodies by surface plasmon resonance (SPR) revealed low nanomolar antiserum affinity for the key heroin metabolite, 6-acetylmorphine (6AM), with minimal cross reactivity to clinically used opioids. Following a series of heroin challenges over six months in vaccinated monkeys, drug-sequestering antibodies caused marked attenuation of heroin potency (>4-fold) in a schedule-controlled responding (SCR) behavioral assay. Overall, these preclinical results provide an empirical foundation supporting the further evaluation and potential clinical utility of an effective heroin vaccine in treating opioid use disorders.

Citing Articles

The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention.

Tuncturk M, Kushwaha S, Heider R, Heider BS R, Oesterle T, Weinshilboum R Int J Neuropsychopharmacol. 2025; 28(2).

PMID: 39831679 PMC: 11792077. DOI: 10.1093/ijnp/pyaf005.

Opioid-Based Haptens: Development of Immunotherapy.

Hosztafi S, Galambos A, Koteles I, Karadi D, Furst S, Al-Khrasani M Int J Mol Sci. 2024; 25(14).

PMID: 39063024 PMC: 11277321. DOI: 10.3390/ijms25147781.

Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl.

Weitzman E, Pierce S, Blakemore L, Murdock A, Angelidou A, Dowling D Vaccine. 2024; 42(24):126082.

PMID: 38991914 PMC: 11401752. DOI: 10.1016/j.vaccine.2024.06.049.

Vaccines to Treat Substance Use Disorders: Current Status and Future Directions.

Lu T, Li X, Zheng W, Kuang C, Wu B, Liu X Pharmaceutics. 2024; 16(1).

PMID: 38258095 PMC: 10820210. DOI: 10.3390/pharmaceutics16010084.

Enhancing Protective Antibodies against Opioids through Antigen Display on Virus-like Particles.

Shafieichaharberoud F, Lang S, Whalen C, Rivera Quiles C, Purcell L, Talbot C Bioconjug Chem. 2023; 35(2):164-173.

PMID: 38113481 PMC: 11259974. DOI: 10.1021/acs.bioconjchem.3c00415.

References

Hartmann G, Krieg A . Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000; 164(2):944-53. DOI: 10.4049/jimmunol.164.2.944. View

Trinidad J, Warner M, Bastian B, Minino A, Hedegaard H . Using Literal Text From the Death Certificate to Enhance Mortality Statistics: Characterizing Drug Involvement in Deaths. Natl Vital Stat Rep. 2016; 65(9):1-15. View

Banks M, Rice K, Negus S . Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy. J Pharmacol Exp Ther. 2010; 335(2):497-505. PMC: 2967402. DOI: 10.1124/jpet.110.169276. View

Stowe G, Vendruscolo L, Edwards S, Schlosburg J, Misra K, Schulteis G . A vaccine strategy that induces protective immunity against heroin. J Med Chem. 2011; 54(14):5195-204. PMC: 3142939. DOI: 10.1021/jm200461m. View

Martell B, Orson F, Poling J, Mitchell E, Rossen R, Gardner T . Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry. 2009; 66(10):1116-23. PMC: 2878137. DOI: 10.1001/archgenpsychiatry.2009.128. View

Jones C . Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013; 132(1-2):95-100. DOI: 10.1016/j.drugalcdep.2013.01.007. View

Hoogsteder P, Kotz D, van Spiegel P, Viechtbauer W, van Schayck O . Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Addiction. 2014; 109(8):1252-9. DOI: 10.1111/add.12573. View

McCluskie M, Pryde D, Gervais D, Stead D, Zhang N, Benoit M . Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol. 2013; 16(1):50-6. DOI: 10.1016/j.intimp.2013.03.021. View

Matyas G, Rice K, Cheng K, Li F, Antoline J, Iyer M . Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine. Vaccine. 2014; 32(13):1473-9. PMC: 4090106. DOI: 10.1016/j.vaccine.2014.01.028. View

10.

Martin W, Jasinski D, Mansky P . Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry. 1973; 28(6):784-91. DOI: 10.1001/archpsyc.1973.01750360022003. View

11.

Anton B, Salazar A, Flores A, Matus M, Marin R, Hernandez J . Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin. 2009; 5(4):214-29. DOI: 10.4161/hv.5.4.7556. View

12.

Valmori D, Souleimanian N, Tosello V, Bhardwaj N, Adams S, ONeill D . Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A. 2007; 104(21):8947-52. PMC: 1885608. DOI: 10.1073/pnas.0703395104. View

13.

Comer S, Collins E, Kleber H, Nuwayser E, Kerrigan J, Fischman M . Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002; 159(4):351-60. PMC: 4079470. DOI: 10.1007/s002130100909. View

14.

Martell B, Mitchell E, Poling J, Gonsai K, Kosten T . Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry. 2005; 58(2):158-64. DOI: 10.1016/j.biopsych.2005.04.032. View

15.

FOX B, Kantak K, Edwards M, Black K, Bollinger B, Botka A . Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med. 1996; 2(10):1129-32. DOI: 10.1038/nm1096-1129. View

16.

Sullivan M, Vosburg S, Comer S . Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berl). 2006; 189(1):37-46. DOI: 10.1007/s00213-006-0509-x. View

17.

Brownstein M . A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci U S A. 1993; 90(12):5391-3. PMC: 46725. DOI: 10.1073/pnas.90.12.5391. View

18.

Rook E, Huitema A, van den Brink W, van Ree J, Beijnen J . Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol. 2008; 1(1):109-18. DOI: 10.2174/157488406775268219. View

19.

Raleigh M, Pravetoni M, Harris A, Birnbaum A, Pentel P . Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. J Pharmacol Exp Ther. 2012; 344(2):397-406. PMC: 3558830. DOI: 10.1124/jpet.112.201194. View

20.

Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M . The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001; 34(6):1193-9. DOI: 10.1053/jhep.2001.29201. View